Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging
Tóm tắt
We have performed pelvic magnetic resonance imaging (MRI) in patients undergoing breast cancer surgery before and after adjuvant drug therapy. Our purpose was to detect any radiographic uterine changes induced by various types of adjuvant therapy on pre- and postmenopausal patients by evaluating prospectively performed MRI. Between September 2004 and December 2007, a total of 41 women with breast cancer (11 premenopausal, 30 postmenopausal) were enrolled. All underwent MRI of the pelvis before and after drug therapy, and uterine changes were evaluated. Postoperative drugs used were selective estrogen receptor modulators (SERMs) including tamoxifen and toremifene (n = 18), aromatase inhibitors (n = 13), and anticancer drugs (n = 10). Only the postmenopausal patients receiving SERMs showed a significant increase in endometrial thickness: from 2.4 ± 0.4 mm before therapy to 4.5 ± 2.6 mm after therapy (P = 0.0485). No statistically significant endometrial change was evident in postmenopausal patients treated with aromatase inhibitors (P = 0.573) or anticancer drugs (P = 0.754). Also, in premenopausal patients treated with SERMs or anticancer drugs, the change in endometrial thickness was not statistically significant (P = 0.958, 0.370). This prospective study using MRI has demonstrated that uterine changes associated with adjuvant drugs for breast cancer occur exclusively in postmenopausal patients receiving SERMs.
Tài liệu tham khảo
Utsumi T, Kobayashi N, Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 2007;14:194–199.
Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004;30:291–301.
Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging 2008;8:135–145.
Varras M, Polyzos D, Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003;24:258–268.
Marttunen MB, Cacciatore B, Hietanen P, Pyrhonen S, Tiitinen A, Wahlstrom T, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal woman. Br J Cancer 2001;84:897–902.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652–1662.
Gerber B, Krause A, Reimer T, Mylonas I, Makovitzky J, Kundt G, et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 2006;12:1245–1250.
Gryspeerdt S, Van Hoe L, Bosmans H, Baert AL, Vergote I, Marchal G. T2-weighted MR imaging of the uterus: comparison of optimized fast spin-echo and HASTE sequences with conventional fast spin-echo sequences. AJR Am J Roentgenol 1998;171:211–215.
Nalaboff KM, Pellerito JS, Ben-Levi E. Imaging the endometrium: disease and normal variants. Radiographics 2001;21:1409–1424.
Kochar SPS, Arora P, Chattopadhyay AB. Tamoxifen therapy for breast cancer and endometrial pathology. MJAFI 2005;61:313–315.
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286–1291.
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M. Pollard S, et al. The ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545–553.
Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination. Breast Cancer Res Treat 1998;47:41–46.
Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233–237.
Nakamura Y, Furutani N, Tamura I, Sanui Y, Sayo M, Ueda K. The number of estrogen receptors on the uterus change with age. Sanfujinkanojissai 2006;55:2083–2086 (in Japanese).
Koshiyama M, Yoshida M, Takemura M, Yura Y, Matsushita K, Hayashi M, et al. Immunohistochemical analysis of distribution of estrogen receptors and progesterone receptors in the postmenopausal endometrium. Acta Obstet Gynecol Scand 1996;75:702–706.
Hachisuga T, Hideshima T, Kawarabayashi T, Eguchi F, Emoto M, Shirakusa T. Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifentreated endometrium. Int J Gynecol Pathol 1999;18:297–303.
Tregón ML, Blümel JE, Tarín JJ, Cano A. The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen. Menopause 2003;10:154–159.
Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002;55:514–519.
Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormonereleasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–353.
Weaver J, McHugo JM, Clark TJ. Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. Br J Radiol 2005;78:394–397.
Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 2000;214:29–38.
Ascher SM, Johnson JC, Barnes WA, Bae CJ, Patt RH, Zeman RK. MR imaging appearance of the uterus in postmenopausal woman receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 1996;200:105–110.
ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–1478.